miRNAs in non-alcoholic fatty liver disease

Non-alcoholic fatty liver disease (NAFLD) is a major cause of liver cirrhosis and hepatocellular carcinoma and is a considerable threat to public health. miRNAs are important post-transcriptional regulators of gene expression, and the dysregulation of miRNAs is involved in various biological process...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers of medicine 2016-12, Vol.10 (4), p.389-396
Main Authors: He, Zhen, Hu, Cheng, Jia, Weiping
Format: Article
Language:English
Subjects:
Animals
Biomarkers - blood
Carcinoma, Hepatocellular - etiology
Disease Progression
Gene expression
Gene Expression Regulation
hepatocellular carcinoma
Humans
Liver - pathology
Liver cancer
Liver cirrhosis
Liver Cirrhosis - etiology
Liver diseases
Liver Neoplasms - etiology
Medicine
Medicine & Public Health
Mice
MicroRNAs - blood
MicroRNAs - genetics
miRNA
Non-alcoholic Fatty Liver Disease - diagnosis
Non-alcoholic Fatty Liver Disease - genetics
nonalcoholic fatty liver disease
nonalcoholic steatohepatitis
Review
Tomography, X-Ray Computed
Ultrasonography
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Non-alcoholic fatty liver disease (NAFLD) is a major cause of liver cirrhosis and hepatocellular carcinoma and is a considerable threat to public health. miRNAs are important post-transcriptional regulators of gene expression, and the dysregulation of miRNAs is involved in various biological processes in the liver, including lipid homeostasis, inflammation, apoptosis, and cell proliferation. Recently, a number of studies have described the association between miRNAs and NAFLD progression and have shown that circulating miRNAs reflect histological changes in the liver. Therefore, circulating miRNAs have potential use for the evaluation of NAFLD severity. In this review, we discuss the involvement of miRNAs in NAFLD pathogenesis and the key role of miRNAs in the screening, diagnosis, and staging of NAFLD.
ISSN:2095-0217
2095-0225
DOI:10.1007/s11684-016-0468-5